CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 158 filers reported holding CLOVIS ONCOLOGY INC in Q4 2021. The put-call ratio across all filers is 1.47 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,000 | -98.0% | 559 | -98.0% | 0.00% | – |
| Q2 2022 | $50,000 | -61.8% | 27,990 | -56.8% | 0.00% | – |
| Q1 2022 | $131,000 | -24.7% | 64,724 | +0.6% | 0.00% | – |
| Q4 2021 | $174,000 | -35.1% | 64,314 | +6.9% | 0.00% | – |
| Q3 2021 | $268,000 | +17.5% | 60,188 | +53.4% | 0.00% | – |
| Q2 2021 | $228,000 | +121.4% | 39,239 | +166.6% | 0.00% | – |
| Q1 2021 | $103,000 | +47.1% | 14,721 | +1.5% | 0.00% | – |
| Q4 2020 | $70,000 | -17.6% | 14,507 | 0.0% | 0.00% | – |
| Q3 2020 | $85,000 | -23.4% | 14,507 | -12.0% | 0.00% | – |
| Q2 2020 | $111,000 | +76.2% | 16,483 | +66.4% | 0.00% | – |
| Q1 2020 | $63,000 | -74.4% | 9,907 | -57.9% | 0.00% | – |
| Q4 2019 | $246,000 | +167.4% | 23,549 | +0.5% | 0.00% | – |
| Q3 2019 | $92,000 | -71.6% | 23,424 | +7.2% | 0.00% | – |
| Q2 2019 | $324,000 | -36.8% | 21,847 | +5.8% | 0.00% | – |
| Q1 2019 | $513,000 | +39.4% | 20,655 | +1.0% | 0.00% | – |
| Q4 2018 | $368,000 | -20.5% | 20,457 | +29.9% | 0.00% | – |
| Q3 2018 | $463,000 | -35.3% | 15,746 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $716,000 | -16.3% | 15,746 | -2.8% | 0.00% | 0.0% |
| Q1 2018 | $855,000 | -34.9% | 16,197 | -16.1% | 0.00% | 0.0% |
| Q4 2017 | $1,313,000 | -11.0% | 19,312 | +7.5% | 0.00% | 0.0% |
| Q3 2017 | $1,476,000 | +1.0% | 17,962 | +14.5% | 0.00% | 0.0% |
| Q2 2017 | $1,462,000 | +83.2% | 15,693 | +24.5% | 0.00% | 0.0% |
| Q1 2017 | $798,000 | +56.5% | 12,603 | +9.4% | 0.00% | – |
| Q4 2016 | $510,000 | +77.1% | 11,516 | +39.9% | 0.00% | – |
| Q3 2016 | $288,000 | +144.1% | 8,231 | -3.0% | 0.00% | – |
| Q2 2016 | $118,000 | -28.0% | 8,483 | 0.0% | 0.00% | – |
| Q1 2016 | $164,000 | -11.8% | 8,483 | +56.8% | 0.00% | – |
| Q4 2015 | $186,000 | -61.0% | 5,411 | +5.0% | 0.00% | -100.0% |
| Q3 2015 | $477,000 | +20.2% | 5,155 | +11.8% | 0.00% | – |
| Q2 2015 | $397,000 | +14.4% | 4,610 | 0.0% | 0.00% | – |
| Q1 2015 | $347,000 | +66.0% | 4,610 | +25.0% | 0.00% | – |
| Q4 2014 | $209,000 | +17.4% | 3,687 | -2.3% | 0.00% | – |
| Q3 2014 | $178,000 | – | 3,774 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |